Aberdare gp iii llc - by aberdare gp iii l l c investment history in Conatus pharmaceuticals inc

Filed on 2014-02-25 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-14-014150.txt Sec File: edgar/data/1582419/0001209191-14-014150-index.htm

2014-02-19 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Gp Iii L L C (Former 10% Owner)

Invested in Conatus Pharmaceuticals Inc sold 36634 shares at $0.00 remaining shares owned 0

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f5 represents a pro-rata in-kind distribution of common stock of the issuer by aberdare gp iii without consideration to its members.
f3 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2014-02-25 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-14-014150.txt Sec File: edgar/data/1582419/0001209191-14-014150-index.htm

2014-02-19 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Gp Iii L L C (Former 10% Owner)

Invested in Conatus Pharmaceuticals Inc bought 36634 shares at $0.00 remaining shares owned 36634

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f4 represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the issuer by aberdare ventures iii and aberdare partners iii described in footnotes 1 and 2.
f3 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2014-02-25 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-14-014150.txt Sec File: edgar/data/1582419/0001209191-14-014150-index.htm

2014-02-19 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Gp Iii L L C (Former 10% Owner)

Invested in Conatus Pharmaceuticals Inc sold 30216 shares at $0.00 remaining shares owned 22203

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f2 represents a pro-rata in-kind distribution of common stock of the issuer by aberdare partners iii, l.p. ("aberdare partners iii") without consideration to its limited partners and its general partner, aberdare gp iii.
f3 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.


Filed on 2014-02-25 by Aberdare Gp Iii, L.L.C. SEC CIK 1582419 Form 4

Accession 0001209191-14-014150.txt Sec File: edgar/data/1582419/0001209191-14-014150-index.htm

2014-02-19 Aberdare Gp Iii Llc (CIK 1582419) through By Aberdare Gp Iii L L C (Former 10% Owner)

Invested in Conatus Pharmaceuticals Inc sold 1283589 shares at $0.00 remaining shares owned 943355

Common Stock Conatus Pharmaceuticals Inc Cnat Transaction code: J Other acquisition or disposition (transaction described in footnotes)

f1 represents a pro-rata in-kind distribution of common stock of the issuer by aberdare ventures iii, l.p. ("aberdare ventures iii") without consideration to its limited partners and its general partner, aberdare gp iii, l.l.c. ("aberdare gp iii").
f3 aberdare gp iii, l.l.c. ("aberdare gp iii") serves as the sole general partner of aberdare ventures iii, l.p. ("aberdare ventures iii") and aberdare partners iii, l.p. ("aberdare partners iii"). as such, aberdare gp iii possesses sole voting and investment control over the securities owned by aberdare ventures iii and aberdare partners iii, and may be deemed to have indirect beneficial ownership of the securities held by aberdare ventures iii and aberdare partners iii. aberdare gp iii, however, owns no securities of the issuer directly and disclaims beneficial ownership of the shares held by aberdare ventures iii and aberdare partners iii except to the extent of its proportionate pecuniary interest therein. klingenstein is a director of the issuer and, accordingly, files separate section 16 reports.